A B S T R A C T Factor IXchapel Hill (Factor IXCH), an abnormal Factor IX molecule isolated from the plasma of a patient with mild hemophilia B, has previously been shown to exhibit delayed activation by Factor XIa and calcium. In this study, we have found that Factor IXCH is cleaved upon incubation with human Factor XIa and calcium; however, cleavage of this protein is not observed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis under nonreducing conditions. Under reducing conditions, the rate of disappearance of the zymogen parallels both the appearance of the heavy chain and the generation of clotting activity. In addition, a protein band that migrates with an apparent molecular weight of 45,000 also increases in parallel with clotting activity. Factor IXCH and normal Factor IX (Factor IXN), after incubation with Factor XIa and calcium, were subjected to amino terminal sequence analysis. Activated Factor IXN is cleaved at an arginine-alanine (Arg-Ala) bond and an arginine-valine (Arg-Val) bond as demonstrated by formation of the three amino terminal sequences corresponding to the amino terminal of the light chain, heavy chain, and activation peptide. However, activated Factor IXCH has only two amino terminal sequences, corresponding to the original amino terminal sequence and the heavy chain (formed by cleavage at the Arg-Val bond). It is concluded that the major defect in Factor IXCH is, the inability of Factor XIa to cleave the Arg-Ala bond at a significant rate. The rate of formation ofclotting activity of Factor IXCH is -60% ofthe rate of formation of clotting activity of Factor IXN. The specific clotting activity of activated Factor IXCH is between 20 and 33% of activated Factor IXN.
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INTRODUCTION
Although it has long been known that Factor IX may be activated by Factor XIa via the intrinsic pathway (1) (2) (3) (4) (5) (6) , it has only recently been demonstrated that Factor VIla in the extrinsic pathway may activate Factor IX (7, 8) . The relative physiological contribution ofboth ofthese factors to Factor IX activation in vivo is unknown. The nomenclature of the cleavage products produced during the activation of normal Factor IX (Factor IXN)1 is shown in Fig. 1 . In the presence of Factor XIa and calcium, an arginine-alanine (Arg-Ala) bond and an arginine-valine (Arg-Val) bond are cleaved resulting in the release of an 11,000-mol wt activation peptide and the formation of a 45,000-mol wt active enzyme, IXa,B (6) . Factor VIIa in the presence of tissue factor and calcium apparently cleaves Factor IXN at similar sites (8) . However, with both enzymes the order of bond cleavage has yet to be confirmed (6, 8) . An inactive intermediate, Factor IXa, is formed when only the Arg-Ala bond is cleaved (6) . With Russell's viper venom and calcium, cleavage occurs at the Arg-Val bond yielding an active product, IXaa, which has a molecular weight of 57,000 (6) . Human Factors IXaa and IXaf3 are reported to have similar clotting activity, whereas bovine Factor IXaa has -50% of the clotting activity of bovine IXa/3 (6, 9, 10) .
In an earlier report from this laboratory some of the properties of Factor IXChapel Hill (Factor IXCH) isolated from a patient with clinically mild hemophilia B were described (11 chased from Johns-Manville, Denver, Colo. All other chemicals were of at least reagent grade or better. Human Factor XIa preparation. 19 g of celite was added to 950 ml of normal human pooled plasma and stirred continuously for 10 min at 37°C before centrifugation at 5,600 g for 10 min. The precipitate was washed three times with 1 liter of distilled water with a 10-min centrifugation at 5,600 g after each wash. The precipitate was then resuspended in 950 ml of 10% NaCl and stirred constantly for 10 min. After centrifugation, the supernatant was dialyzed overnight against three changes of 0.15 M NaOAc, 0.02% NaN3, pH 5.2.
After dialysis the crude Factor XIa was passed over a carboxymethylcellulose (12) column (2.5 x 30 cm) equilibrated with 0.15 M NaOAc (pH 5.2). The column was washed with 250 ml of0. 15 M NaOAc (pH 5.2). Human Factor XIa was eluted with a linear gradient of NaOAc 0.15 M (pH 5.2) to 0.33 M sodium phosphate, 0.5 M NaCl (pH 6.8) (250 ml each). Fractions containing Factor XIa activity, as measured by shortening of a modified nonactivated partial thromboplastin time (13), were pooled and dialyzed overnight against three changes of4 liters of 0.15 M NaOAc (pH 5.2). The dialyzed material was concentrated with PEG 20,000 to a final volume of 3.5 ml and then placed on a Sephadex G 200 column (3.0 x 60 cm) equilibrated with NaOAc 0.15 M (pH 5.2). Fractions containing human Factor XIa activity were pooled and placed on a heparin Sepharose column (2.0 x 5.0 cm) previously equilibrated with 0.15 M NaOAc (pH 5.2). The column was washed with 100 ml of 0.15 M NaOAc (pH 5.2), 0.2 M NaCl (pH 5.2) and the Factor XIa eluted with 0.15 M NaOAc 2.0 M NaCl (pH 5.2). Factor XIa fractions were again pooled and dialyzed overnight against 0.15 M NaOAc (pH 5.2). The dialyzed material was finally concentrated with PEG 20,000 to a volume of 3.5 ml. Portions of 0.5 ml were stored in polypropylene tubes at -700C. The final material, diluted 1:10 in 0.05 M Tris HC1 (pH 7.4) clotted normal pooled plasma in plastic tubes in 47 s but had no effect on plasma obtained from a patient with hemophilia B with undetectable Factor IX clotting activity and antigen levels nor on fibrinogen after 5 min of incubation at 37°C. The Factor XIa corrected the clotting defect ofplasma obtained from a patient severely deficient in Factor XI. The Factor XIa required calcium for complete activation of Factor IX, indicating that the Factor XIa contained an insignificant quantity of kallikrein.
Preparation of Factor IXN and Factor IXCH. Both proteins were prepared essentially as described (11 (11) . Concentration of Factor XIa was based on the extinction coefficient 13.4 (6). 0.10 ml of plasma with undetectable Factor IX clotting activity and antigen to 0.10 ml of the sample to be tested and incubating at 37°C in a 12 x 75-mm polystyrene tube for 60 s. 0.2 ml of a buffered Thrombofax solution (5 ml of calcium imidazole saline,3 4.5 ml of normal saline, and 0.5 ml of Thrombofax) was then added to the mixture and a stopwatch was started. The tubes were shaken 20 times and after 30 s at 37°C, the clotting time was determined. Both Factor IXN and Factor IXCH were tested at the same time in an identical manner. After determining that Factor IXN was fully activated after 30-min incubation, a standard curve was made of the normal product by preparing dilutions of the fully activated material in 0.05 M Tris (pH 7.4) of 50, 33, 20, 12.5, and 6.25%. The clotting times were plotted on a log-log graph and a straight line was obtained as described by DiScipio et al. (6) . From this standard curve the percent activation was extrapolated for the time points previously measured. After 30 min all of the Factor IXN zymogen had been cleaved to the activated product as demonstrated by electrophoresis on 7.5% polyacrylamide gels under reducing conditions with ,3-mercaptoethanol as described by Weber and Osborn (14) .
The specific activity of Factor IXCH was determined by running the activation as previously described with three different Factor XIa concentrations yielding enzyme substrate ratios of 1 (Fig. 2) . One band migrated with a mobility identical to that of the heavy chain band from Factor IXN. The other band, however, had an apparent mol wt of 45,000, which corresponded to a cleavage product composed of the light chain and activation peptide found on cleavage of both Factor IXN and Factor IXCH by Russell's viper venom (not shown).
The relative rates of cleavage of Factor IXN and Factor IXCH were determined by scanning polyacrylamide gels of reduced samples taken at various times of incubation (Fig. 3A and B) . With both Factor IXN and Factor IXCH the rate ofdecrease in the zymogen band was nearly identical to the rate of increase in the heavy chain band (Fig. 3B) . However, the rate of cleavage of Factor IXCH was 60% of the rate of Factor IXN cleavage under these experimental conditions. The rate of increase in the intermediate 45,000 mol wt band for Factor IXCH was also nearly identical to the rate of decrease in Factor IXCH zymogen (Fig. 3A) . A 45,000 mol wt band was also apparent in gels from Factor IXN but was present in only small amounts and remained essentially constant during the period of incubation (Fig. 3A) . The light chain band from Factor IXN cleavage did not appear in the first 10 min of incubation but increased significantly after that time (Fig. 3B) In an attempt to confirm the identity of the cleavage products formed by incubation of Factor IXCH with Factor XIa, samples were prepared for sequence analysis of the amino terminal regions of the resulting activation products. (The samples used were those shown in Fig. 2 ). Unactivated Factor IXN and Factor IXCH were identical in amino acid sequence through the first six positions tyrosine-asparagine-serineglycine-lysine-leucine (Tyr-Asn-Ser-Gly-Lys-Leu). The first sequence cycle of activated Factor IXN indicated three amino terminals; Tyr, Ala, Val as shown in Table I . The amino acids found in the subsequent cycles likewise corresponded to the reported sequences (6) of the light chain, the activation peptide, and the heavy chain. In contrast, sequence analysis of Factor XIa-activated Factor IXCH revealed only two sequences, corresponding to the original amino terminal of the zymogen (Tyr) and the amino terminal of the heavy chain (Val) ( Table I) 10 ,ug of protein were removed and the 1% SDS and 5 mM EDTA. The proteii dithiothreitol at 56°C for 60 min. Aft( 7.5% disc gel electrophoresis, the prote Coomassie Blue and the gels were scan each peak were determined and th calculated.
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It is interesting to note that the apparent molecular weight of the light chain and the light chain-activation peptide component are somewhat heavier as judged by SDS polyacrylamide disc gel electrophoresis than expected. Precise explanation for this observation cannot be given; however, it is well-known that glycoproteins may migrate with higher apparent molecular weights than expected in SDS-polyacrylamide gel electrophoresis (26) . From the reported carbohydrate composition of human Factor IX (6), it is known that all three peptides (heavy chain, light chain, and activation peptide) contain significant carbohydrate and, thus, could migrate in an unexpected manner on SDS disc gel electrophoresis.
By comparison with Factor IXN, Factor IXCH is distinguishable by a slower rate of activation (-60%) and a lower final specific activity (-30%). These observations can be contrasted with the 5% Factor IX activity determined for Factor IXCH by a one-stage clotting assay.
The relatively low specific activity ofthe fully activated Factor IXCH may be related to the fact that Factor IXCH is cleaved by Factor XIa to a Factor IXaa form rather than to the Factor IXaf3 form. 
